Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

Another Top Pfizer Exec Resigns!


What is going on at Pfizer?

They seem to have a string of long-term executives leaving in a very short amount of time, maybe they cashed in on their stock options that no doubt surged to unprecedented levels over the course of this engineered ‘pandemic’.

Maybe they aren’t comfortable with what is going on, or maybe they simply fear the massive backlash that has already begun, but will no doubt take a turn for the worst for all those involved in the very near future.

Perhaps that is why they bolt from the scene when confronted by reporters. Iv’e seen folks run from the press or hide their faces before, but bolt? That unique honor belongs to one Pfizer executive.

Pfizer C.F.O. Frank D’Amelio made headlines today when his retirement was announced, and Pfizer is now reportedly searching for a new C.F.O. to take the seasoned executive’s place.

Here’s more on the story:

The Wall Street Journal had more:

Mr. D’Amelio also serves as Pfizer’s executive vice president of global supply. In connection with Mr. D’Amelio’s planned retirement, Pfizer named Mike McDermott as chief global supply officer, effective Jan. 1. Mr. McDermott, who is currently president of global supply, will join Pfizer’s leadership team and report to Chief Executive Albert Bourla.

SIGN THE PETITION: Release The Epstein Client List!

The finance chief’s retirement comes as Pfizer ramps up production of its Covid-19 vaccine.

Business Wire quotes Pfizer C.E.O. Albert Bourla on D’Amelio’s departure:

“I want to thank Frank for his many years of service to Pfizer as CFO and for the impact he has had on the Company and the patients we serve,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

“Frank has driven a strategic vision for the Company’s financial success, and he leaves Pfizer in a strong position for future growth having been instrumental in our multi-year transformation to an industry leading, science-based biopharmaceutical company.”


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!